Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
Last week, we reported on new real-world data from the US Centers for Disease Control and Prevention (CDC) on nirsevimab effectiveness for prevention of respiratory syncytial virus (RSV)–associated hospitalization among infants entering their first RSV season.
The study
Using data from the New Vaccine Surveillance Network, researchers examined the effectiveness of nirsevimab in a sample of 699 infants hospitalized with acute respiratory illness (ARI) at 4 US sites (Pittsburgh, Seattle, Houston, and Nashville) during their first RSV season between October 1, 2023, and February 24, 2024. Among the cohort, there were 407 participants who received a positive RSV test result (ie, case-patients) and 292 who received a negative RSV test result (ie, control patients).
The findings
Nirsevimab was 90% effective against RSV-associated hospitalization, with a median time of 45 days from receipt of the drug to ARI symptom onset.
Authors' comment
"This finding supports current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab, to reduce the risk for RSV-associated hospitalization in their first RSV season.”
